Protocol Ledger

NCT06829784 · Phase III · RECRUITING

TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection

Interventional Phase III clinical trial protocol NCT06829784 sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-21 Enrollment: 660 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06829784
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)660 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06829784
Protocol FieldVerified Registry Value
NCT IdentifierNCT06829784
Consolidated Lead SponsorShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment660 participants (ESTIMATED)
Registered Start Date2025-03-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI